Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 2.29 INR
Change Today -0.04 / -1.72%
Volume 6.0K
GLL On Other Exchanges
Symbol
Exchange
Mumbai
As of 2:51 AM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

gennex laboratories ltd (GLL) Snapshot

Open
2.29
Previous Close
2.33
Day High
2.29
Day Low
2.29
52 Week High
11/26/14 - 4.75
52 Week Low
05/29/14 - 0.88
Market Cap
289.7M
Average Volume 10 Days
51.5K
EPS TTM
0.03
Shares Outstanding
126.5M
EX-Date
09/10/01
P/E TM
77.2x
Dividend
--
Dividend Yield
--
Current Stock Chart for GENNEX LABORATORIES LTD (GLL)

Related News

No related news articles were found.

gennex laboratories ltd (GLL) Related Businessweek News

No Related Businessweek News Found

gennex laboratories ltd (GLL) Details

Gennex Laboratories Limited manufactures and sells bulk drugs, intermediates, and biotech products. It provides Guaiphenesin, an expectorant used as a mucolyte; Methocarbamol, a non-narcotic, non-toxic drug used in treating conditions, such as spasm and pain associated with acute musculoskeletal disorders, tension, myalgia, acute traumatic muscle spasm, acute disc prolapse, painful shoulder syndrome, etc.; and Phenazopyridine Hydrochloride, a drug that has analgesic effect in the urinary tract and gives symptomatic relief of dysuria. The company also offers Fluconazole, a bis-triazole anti fungal drug used for the treatment of fungal infections; Metformin Hcl, a non-insulin anti-diabetic; Ambroxol Hcl, a secretolytic agent used in the treatment of respiratory diseases associated with viscid or excessive mucus; and Melitracen Hydrochloride, a tricyclic antidepressant. It offers its products in India, Dubai, Germany, the Netherlands, Iran, Peru, Colombia, and other counties. The company was formerly known as Prudential Pharmaceuticals Limited. Gennex Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.

Founded in 1990

gennex laboratories ltd (GLL) Top Compensated Officers

Managing Director, Director and Member of Inv...
Total Annual Compensation: --
Whole Time Director, Member of Audit Committe...
Total Annual Compensation: 1.1M
Compensation as of Fiscal Year 2014.

gennex laboratories ltd (GLL) Key Developments

Gennex Laboratories Limited Reports Unaudited Standalone Earnings Results for Third Quarter and Nine Months Ended December 31, 2014

Gennex Laboratories Limited reported unaudited standalone earnings results for third quarter and nine months ended December 31, 2014. For the quarter, the company reported net sales/income from operations of INR 66.298 million against INR 102.006 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 0.274 million against INR 6.566 million a year ago. Profit from ordinary activities before tax was INR 0.469 million against INR 6.549 million a year ago. Net profit for the period was INR 0.469 million or INR 0.004 per basic and diluted share before and after extraordinary items against INR 6.549 million or INR 0.052 per basic and diluted share before and after extraordinary items for the same period a year ago. For the nine months, the company reported net sales/income from operations of INR 226.206 million against INR 250.461 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 8.054 million against INR 8.099 million a year ago. Profit from ordinary activities before tax was INR 6.918 million against INR 7.551 million a year ago. Net profit for the period was INR 6.468 million or INR 0.051 per basic and diluted share before and after extraordinary items against INR 7.551 million or INR 0.060 per basic and diluted share before and after extraordinary items for the same period a year ago.

Gennex Laboratories Limited, Board Meeting, Feb 14, 2015

Gennex Laboratories Limited, Board Meeting, Feb 14, 2015. Agenda: To consider the quarterly results.

Gennex Laboratories Limited Reports Unaudited Standalone Earnings Results for the Second Quarter and Six Months Ended September 30, 2014

Gennex Laboratories Limited reported unaudited standalone earnings results for the second quarter and six months ended September 30, 2014. For the quarter, the company reported net sales/income from operation of INR 82.983 million against INR 80.643 million a year ago. Profit from operations before other income, finance costs and exceptional items were INR 3.914 million against INR 0.483 million a year ago Profit from ordinary activities before tax was INR 2.989 million against INR 0.155 million a year ago. Net profit for the period was INR 2.539 million or INR 0.020 per basic and diluted share before and after extraordinary items against INR 0.155 million or INR 0.001 per basic and diluted share before and after extraordinary items a year ago. For the six months, the company reported net sales/income from operation of INR 159.908 million against INR 148.455 million a year ago. Profit from operations before other income, finance costs and exceptional items were INR 7.780 million against INR 1.533 million a year ago Profit from ordinary activities before tax was INR 6.449 million against INR 1.002 million a year ago. Net profit for the period was INR 5.999 million or INR 0.046 per basic and diluted share before and after extraordinary items against INR 1.002 million or INR 0.008 per basic and diluted share before and after extraordinary items a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GLL:IN 2.29 INR -0.04

GLL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for GLL.
View Industry Companies
 

Industry Analysis

GLL

Industry Average

Valuation GLL Industry Range
Price/Earnings 100.0x
Price/Sales 0.8x
Price/Book 1.1x
Price/Cash Flow 29.5x
TEV/Sales 0.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENNEX LABORATORIES LTD, please visit www.gennexlab.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.